Human vWF-A1 (Research Grade Caplacizumab Biosimilar) Alexa Fluor® 647-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: vWF-A1

Caplacizumab is a humanized VHH immunoglobulin that binds to the A1 domain of the large von Willdebrand factor resulting in the inhibition of the interaction of glycoprotein GPIb-IX-V receptor on platelet surface.  The result of neutralizing of the von Willedebrand factor is reduced platelet aggregation.  Caplacizumab has been approved for the treatment of acute thrombotic thrombocytopenic purpura (aTTP), and has been shown to reduce the occurrence of thromboembolic events.

Product Datasheets

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Related Research Areas

• Alpha Granule Soluble Molecules
• Coagulation
• Endothelial Cell Coagulation Molecules
• Endothelial Cell Markers
• Extracellular Matrix Molecules
• Megakaryocytes
• Preeclampsia